WG
SUPN icon

Winton Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Winton Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,569
Closed -$392K – 1446
2020
Q4 		$392K Sell
15,569
-6,468
-29% -$139K 0.03% 912
2020
Q3 		$459K Sell
22,037
-129,129
-85% -$2.93M 0.01% 1144
2020
Q2 		$3.59M Sell
151,166
-212,034
-58% -$4.68M 0.09% 369
2020
Q1 		$6.53M Buy
363,200
+20,849
+6% +$438K 0.17% 158
2019
Q4 		$8.12M Sell
342,351
-181,074
-35% -$4.4M 0.11% 305
2019
Q3 		$14.4M Buy
523,425
+149,559
+40% +$4.43M 0.17% 168
2019
Q2 		$12.4M Buy
373,866
+70,566
+23% +$2.42M 0.24% 153
2019
Q1 		$10.6M Buy
303,300
+16,515
+6% +$614K 0.21% 184
2018
Q4 		$9.53M Buy
286,785
+263,097
+1,111% +$11.3M 0.21% 214
2018
Q3 		$1.19M Buy
23,688
+14,717
+164% +$727K 0.03% 373
2018
Q2 		$537K Sell
8,971
-6,424
-42% -$333K 0.01% 622
2018
Q1 		$705K Buy
+15,395
New +$642K 0.02% 635

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Winton Group's SUPN Position: Q1 2021 in Review

Winton Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 15,569 shares — an estimated $392K sold.

Winton Group first reported a position in SUPN in Q1 2018 and held it in 12 quarters. The position peaked at $14.4M in Q3 2019. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Winton Group reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Winton Group sold 15,569 Supernus Pharmaceuticals shares in Q1 2021, an estimated $392K.
  • Winton Group first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • Winton Group's Supernus Pharmaceuticals position peaked at $14.4M in Q3 2019.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.